Infusion of Reconstituted High-Density Lipoprotein, CSL112, in Patients With Atherosclerosis: Safety and Pharmacokinetic Results From a Phase 2a Randomized Clinical Trial

BACKGROUND: CSL112 is a new formulation of human apolipoprotein A-I (apoA-I) being developed to reduce cardiovascular events following acute coronary syndrome. This phase 2a, randomized, double-blind, multicenter, dose-ranging trial represents the first clinical investigation to assess the safety an...

Descripción completa

Detalles Bibliográficos
Autores principales: Tricoci, Pierluigi, D’Andrea, Denise M, Gurbel, Paul A, Yao, Zhenling, Cuchel, Marina, Winston, Brion, Schott, Robert, Weiss, Robert, Blazing, Michael A, Cannon, Louis, Bailey, Alison, Angiolillo, Dominick J, Gille, Andreas, Shear, Charles L, Wright, Samuel D, Alexander, John H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4599471/
https://www.ncbi.nlm.nih.gov/pubmed/26307570
http://dx.doi.org/10.1161/JAHA.115.002171

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4599471/
https://www.ncbi.nlm.nih.gov/pubmed/26307570
http://dx.doi.org/10.1161/JAHA.115.002171

Ejemplares similares